NDAORALTABLET
Approved
Dec 1987
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
3/8 — Basic
PRINIVIL (lisinopril) by Merck & Co. is angiotensin-converting enzyme (ace) in human subjects and animals. First approved in 1987.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PRINIVIL (lisinopril) is an oral ACE inhibitor tablet approved in 1987 for hypertension, heart failure, and diabetic nephropathy. It works by inhibiting angiotensin-converting enzyme, reducing angiotensin II formation and aldosterone secretion, leading to decreased vasopressor activity and blood pressure reduction. The drug is effective across racial populations, though Black patients show a smaller monotherapy response that normalizes when combined with hydrochlorothiazide.
LOE Approaching
As loss of exclusivity approaches, PRINIVIL teams face declining revenue and shrinking headcount; career moves to growth-stage franchises within Merck are strategically important.
Mechanism of Action
angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II. Angiotensin II also stimulates aldosterone secretion by the adrenal cortex. The beneficial effects of…
Indications
Worked on PRINIVIL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.